Table 1.
Characteristics of NSCLC patients
| Patient characteristics | n (% of patients) | |
|---|---|---|
| Total no. of patients | 444 | |
| Median age, range (age at diagnosis, years) | 57 (48) | |
| Gender | ||
| Male | 318 (71.6) | |
| Female | 126 (28.4) | |
| Performance status (PS) (n = 443)a | ||
| 0–1 | 425 (95.9) | |
| 2 | 18 (4.1) | |
| Tumor-node-metastasis (TNM) stage | ||
| IIIA | 44 (9.9) | |
| IIIB | 131 (29.5) | |
| IV | 269 (60.6) | |
| Histopathological type | ||
| Adenocarcinoma | 267 (60.1) | |
| Squamous cell | 89 (20.0) | |
| Adenosquamocarcinoma | 16 (3.6) | |
| Otherb | 72 (16.2) | |
| Chemotherapy regimens | ||
| Platinum-navelbine | 231 (52.0) | |
| Platinum-gemcitabine | 77 (17.3) | |
| Platinum-paclitaxel | 89 (20.0) | |
| Platinum-docetaxel | 22 (5.0) | |
| Other platinum combinations | 25 (5.6) | |
| Smoking status | ||
| Current | 239 (53.8) | |
| Former | 9 (2.0) | |
| Never | 196 (44.1) | |
| Response (n = 417)a | ||
| Complete response (CR) | 1 (0.2) | |
| Partial response (PR) | 75 (18.0) | |
| Stable disease (SD) | 290 (69.5) | |
| Progressive disease (PD) | 51 (12.2) | |
| Toxicity outcomes | ||
| Grade 3 or 4 toxicity (n = 382)a | 142 (37.2) | |
| Grade 3 or 4 hematologic toxicity (n = 401)a | 129 (32.2) | |
| Grade 3 or 4 gastrointestinal toxicity (n = 403)a | 27 (6.7) | |
| p53 p.Pro72Arg(rs1042522) (n = 441)a | ||
| C/C | 85 (19.3) | |
| C/G | 209 (47.4) | |
| G/G | 147 (33.3) | |
| MDM2 c.−461C>G(rs937282) (n = 426)a | ||
| C/C | 226 (53.1) | |
| C/G | 157 (36.9) | |
| G/G | 43 (10.1) | |
| MDM2 c.14 + 309T>G(rs2279744) (n = 430)a | ||
| G/G | 121 (28.1) | |
| G/T | 293 (68.1) | |
| T/T | 16 (3.7) |
a
available data from these indicated subjects.
b
includes mixed cell, neuroendocrine carcinoma and unclassified carcinoma.